DataMeds Applauds FDA's Proposed Interim Access Policy for Compounding Using Certain Peptides and Provides Corexa Health's Peptides Roadmap
DataMeds AI applauded a new FDA proposed interim access policy that would loosen restrictions on compounding certain peptides, building on a recent PCAC recommendation covering six peptides. Its subsidiary Corexa Health laid out a roadmap to capitalize: the 503A compounding pharmacy will fill peptide prescriptions once the policy takes effect, the distribution division (licensed in all 50 states, 40,000 sq ft Lakeland warehouse) will supply drug substance and 3PL services, and the hub division will route prescriptions via the Health Lives Here app to a network of 6,500+ independent pharmacies.
Key figures
- Warehouse sqft
- 40000
- Us compounding market 2025
- $18 billion
- Us compounding market 2035e
- over $34 billion
- Independent pharmacy network
- 6,500+
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.